Department of Epidemiology, The Johns Hopkins Bloomberg
School of Public Health, Baltimore, Maryland (Kathy J.
Helzlsouer); The Prevention and Research Center, The
Weinberg Center for Women’s Health and Medicine,
Mercy Medical Center, Baltimore, Maryland (Kathy J.
Helzlsouer); and Division of Epidemiology, Department
of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-
Ingram Cancer Center, Vanderbilt University School of
Medicine, Nashville, Tennessee (Xiao-Ou Shu, Wei Zheng).
This work was supported by the Extramural Research
Program of the National Institutes of Health, Division of
Cancer Control and Population Sciences, National Cancer
Institute (NCI) (Bethesda, Maryland) and the Intramural
Research Program of the National Institutes of Health, Di-
vision of Cancer Epidemiology and Genetics, NCI. The
New York University Women’s Health Study was supported
by the NCI (grant R01 CA098661). The Multiethnic Cohort
Study was supported by the NCI (grants R37 CA54281, P01
CA33619, R01 CA063464, and N01-PC35137). The Shang-
hai Men’s Health Study was supported by the NCI (grant
R01 CA82729). The Shanghai Women’s Health Study was
supported by the NCI (grants R37 CA70867 and N02-CP-
11010-66). The Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial was supported by contracts from
the NCI to the University of Colorado, Denver, Colorado
(grant N01-CN-25514); Georgetown University, Washing-
ton, DC (grant N01-CN-25522); the Paciﬁc Health Research
Institute, Honolulu, Hawaii (grant N01-CN-25515); the
Henry Ford Health System, Detroit, Michigan (grant N01-
CN-25512); the University of Minnesota, Minneapolis,
Minnesota (grant N01-CN-25513); Washington University,
St. Louis, Missouri (grant NO1-CN-25516); the University
of Pittsburgh, Pittsburgh, Pennsylvania (grant N01-CN-
25511); the University of Utah, Salt Lake City, Utah (grant
N01-CN-25524); the Marshﬁeld Clinic Research Founda-
tion, Marshﬁeld, Wisconsin (grant N01-CN-25518); the
University of Alabama, Birmingham, Alabama (grant
NO1-CN-75022); Westat, Inc., Rockville, Maryland (grant
N01-CN-25476); and the University of California, Los An-
geles, Los Angeles, California (grant NO1-CN-25404). The
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
was supported by funding provided by the Intramural Re-
search Program of the NCI and US Public Health Service
contracts (N01-CN-45165, N01-RC-45035, N01-RC-
37004). CLUE was supported by the National Institute on
Aging (grant U01 AG018033) and the NCI (grants R01
CA105069, K07 CA73790). The participation of CLUE
investigators was also supported by an NCI contract
awarded to Mercy Medical Center through the University
of Hawaii (Honolulu, Hawaii). The Cancer Prevention
Study II Nutrition Cohort was supported by the American
Cancer Society (Atlanta, Georgia).
The authors thank Dr. Karen Phinney of the National
Institute of Standards and Technology for providing
the SRM 972 Vitamin D in Human Serum used in this
Members of the VDPP Upper GI Writing Committee:
Christian C. Abnet, Yu Chen, Wong-Ho Chow, Yu-Tang
Gao, Kathy J. Helzlsouer, Loı
c Le Marchand, Marjorie L.
McCullough, James M. Shikany, and Xiao-Ou Shu.
This report is based at least in part on information pro-
vided by the Maryland Cancer Registry, Maryland Depart-
ment of Health and Mental Hygiene.
Dr. Ronald L. Horst is the President and Chief Executive
Ofﬁcer of Heartland Assays, Inc.
1. Fleet JC. Molecular actions of vitamin D contributing to
cancer prevention. Mol Aspects Med. 2008;29(6):388–396.
2. Grant WB. An estimate of premature cancer mortality in the
U.S. due to inadequate doses of solar ultraviolet-B radiation.
3. Grant WB. Does solar ultraviolet irradiation affect cancer
mortality rates in China? Asian Pac J Cancer Prev. 2007;
4. Tuohimaa P, Pukkala E, Sce
lo G, et al. Does solar exposure, as
indicated by the non-melanoma skin cancers, protect from
solid cancers: vitamin D as a possible explanation. Eur J
5. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of
predictors of vitamin D status and cancer incidence and mor-
tality in men. J Natl Cancer Inst. 2006;98(7):451–459.
6. Launoy G, Milan C, Day NE, et al. Diet and squamous-cell
cancer of the oesophagus: a French multicentre case-control
study. Int J Cancer. 1998;76(1):7–12.
7. La Vecchia C, Ferraroni M, D’Avanzo B, et al. Selected mi-
cronutrient intake and the risk of gastric cancer. Cancer Epi-
demiol Biomarkers Prev. 1994;3(5):393–398.
8. Pelucchi C, Tramacere I, Bertuccio P, et al. Dietary intake of
selected micronutrients and gastric cancer risk: an Italian case-
control study. Ann Oncol. 2009;20(1):160–165.
9. Chen W, Dawsey SM, Qiao YL, et al. Prospective study of
serum 25(OH)-vitamin D concentration and risk of oesophageal
and gastric cancers. Br J Cancer. 2007;97(1):123–128.
10. Abnet CC, Chen W, Dawsey SM, et al. Serum 25(OH)-vitamin
D concentration and risk of esophageal squamous dysplasia.
Cancer Epidemiol Biomarkers Prev. 2007;16(9):1889–1893.
11. Gallicchio L, Helzlsouer KJ, Chow WH, et al. Circulating 25-
hydroxyvitamin D and the risk of rarer cancers: design
and methods of the Cohort Consortium Vitamin D Pooling
Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):
12. Wagner D, Hanwell HE, Vieth R. An evaluation of automated
methods for measurement of serum 25-hydroxyvitamin D.
Clin Biochem. 2009;42(15):1549–1556.
13. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-
hydroxyvitamin D status of the US population: 1988–1994 com-
pared with 2000–2004. Am J Clin Nutr . 2008;88(6):1519–1527.
14. Viechtbauer W. MiMa: an S-Plus/R function to ﬁt meta-
analytic mixed-, random-, and ﬁxed-effects models [computer
software and manual]. 2006. (http://www.wvbauer.com/
downloads.html). (Accessed February 6, 2009).
15. McCullough ML, Weinstein SJ, Freedman DM, et al. Corre-
lates of circulating 25-hydroxyvitamin D: Cohort Consortium
Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol.
16. Stolzenberg-Solomon RZ, Vieth R, Azad A, et al. A pro-
spective nested case-control study of vitamin D status and
pancreatic cancer risk in male smokers. Cancer Res. 2006;
17. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Cir-
culating 25-hydroxyvitamin D and risk of pancreatic cancer:
Circulating 25(OH)D and Upper GI Cancer Risk 105
Am J Epidemiol 2010;172:94–106